Petvivo Holdings Inc (PETV)

$0.65

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $0.60
    $0.65
    $0.65
    downward going graph

    7.54%

    Downside

    Day's Volatility :7.54%

    Upside

    0.0%

    downward going graph
  • $0.55
    $2.95
    $0.65
    downward going graph

    15.38%

    Downside

    52 Weeks Volatility :81.36%

    Upside

    77.97%

    downward going graph

Returns

PeriodPetvivo Holdings IncIndex (Russel 2000)
3 Months
-20.74%
0.0%
6 Months
-38.12%
0.0%
1 Year
-68.91%
0.0%
3 Years
-81.85%
-20.2%

Highlights

Market Capitalization
12.0M
Book Value
$0.04
Earnings Per Share (EPS)
-0.78
PEG Ratio
0.0
Wall Street Target Price
7.0
Profit Margin
0.0%
Operating Margin TTM
-5489.99%
Return On Assets TTM
-239.04%
Return On Equity TTM
-1552.87%
Revenue TTM
968.7K
Revenue Per Share TTM
0.07
Quarterly Revenue Growth YOY
-61.6%
Gross Profit TTM
-85.6K
EBITDA
-10.5M
Diluted Eps TTM
-0.78
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Petvivo Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 976.92%

Current $0.65
Target $7.00

Company Financials

FY18Y/Y Change
Revenue
7.1K
↑ 0.0%
Net Income
-15.5M
↑ 0.0%
Net Profit Margin
-218.0K%
↑ 0.0%
FY19Y/Y Change
Revenue
77.9K
↑ 993.99%
Net Income
-4.8M
↓ 69.37%
Net Profit Margin
-6.1K%
↑ 211912.33%
FY20Y/Y Change
Revenue
3.6K
↓ 95.4%
Net Income
-2.1M
↓ 55.55%
Net Profit Margin
-58.9K%
↓ 52839.53%
FY21Y/Y Change
Revenue
12.6K
↑ 250.56%
Net Income
-3.8M
↑ 77.38%
Net Profit Margin
-29.8K%
↑ 29119.34%
FY22Y/Y Change
Revenue
115.6K
↑ 818.95%
Net Income
-4.9M
↑ 31.73%
Net Profit Margin
-4.3K%
↑ 25549.47%
FY23Y/Y Change
Revenue
917.2K
↑ 693.49%
Net Income
-8.7M
↑ 76.09%
Net Profit Margin
-948.77%
↑ 3326.65%
Q3 FY22Q/Q Change
Revenue
223.3K
↑ 283.81%
Net Income
-2.1M
↑ 6.7%
Net Profit Margin
-938.57%
↑ 2437.68%
Q4 FY22Q/Q Change
Revenue
510.1K
↑ 128.46%
Net Income
-2.3M
↑ 9.96%
Net Profit Margin
-451.75%
↑ 486.82%
Q1 FY23Q/Q Change
Revenue
125.6K
↓ 75.38%
Net Income
-2.3M
↑ 1.07%
Net Profit Margin
-1.9K%
↓ 1402.54%
Q2 FY23Q/Q Change
Revenue
117.2K
↓ 6.7%
Net Income
-2.9M
↑ 24.24%
Net Profit Margin
-2.5K%
↓ 614.99%
Q3 FY23Q/Q Change
Revenue
207.4K
↑ 76.96%
Net Income
-3.7M
↑ 26.53%
Net Profit Margin
-1.8K%
↑ 703.73%
Q4 FY23Q/Q Change
Revenue
595.9K
↑ 187.36%
Net Income
-1.7M
↓ 52.21%
Net Profit Margin
-293.65%
↑ 1471.9%
FY18Y/Y Change
Total Assets
1.9M
↑ 0.0%
Total Liabilities
1.1M
↑ 0.0%
FY19Y/Y Change
Total Assets
691.1K
↓ 63.56%
Total Liabilities
1.5M
↑ 42.59%
FY20Y/Y Change
Total Assets
522.5K
↓ 24.4%
Total Liabilities
1.6M
↑ 1.48%
FY21Y/Y Change
Total Assets
835.2K
↑ 59.85%
Total Liabilities
1.7M
↑ 11.13%
FY22Y/Y Change
Total Assets
7.4M
↑ 789.24%
Total Liabilities
1.4M
↓ 16.83%
FY23Y/Y Change
Total Assets
2.4M
↓ 67.16%
Total Liabilities
1.7M
↑ 18.97%
Q3 FY22Q/Q Change
Total Assets
4.1M
↓ 29.23%
Total Liabilities
1.5M
↑ 1.11%
Q4 FY22Q/Q Change
Total Assets
2.6M
↓ 36.6%
Total Liabilities
1.8M
↑ 19.95%
Q1 FY23Q/Q Change
Total Assets
2.4M
↓ 5.04%
Total Liabilities
1.7M
↓ 3.94%
Q2 FY23Q/Q Change
Total Assets
3.1M
↑ 27.07%
Total Liabilities
2.7M
↑ 57.59%
Q3 FY23Q/Q Change
Total Assets
4.1M
↑ 31.06%
Total Liabilities
3.1M
↑ 13.78%
Q4 FY23Q/Q Change
Total Assets
3.6M
↓ 10.63%
Total Liabilities
2.7M
↓ 11.01%
FY18Y/Y Change
Operating Cash Flow
-143.0K
↑ 0.0%
Investing Cash Flow
-62.9K
↑ 72.55%
Financing Cash Flow
204.7K
↑ 0.0%
FY19Y/Y Change
Operating Cash Flow
-736.4K
↑ 414.94%
Investing Cash Flow
-103.8K
↑ 64.99%
Financing Cash Flow
609.4K
↑ 197.75%
FY20Y/Y Change
Operating Cash Flow
-496.6K
↓ 32.57%
Investing Cash Flow
-65.2K
↓ 37.19%
Financing Cash Flow
565.9K
↓ 7.13%
FY21Y/Y Change
Operating Cash Flow
-1.0M
↑ 110.9%
Investing Cash Flow
-160.2K
↑ 145.67%
Financing Cash Flow
1.2M
↑ 115.67%
FY22Y/Y Change
Operating Cash Flow
-4.2M
↑ 298.63%
Investing Cash Flow
-183.2K
↑ 14.37%
Financing Cash Flow
10.4M
↑ 755.51%
FY23Y/Y Change
Operating Cash Flow
-6.8M
↑ 62.74%
Investing Cash Flow
-423.9K
↑ 131.43%
Financing Cash Flow
1.6M
↓ 84.8%
Q3 FY22Q/Q Change
Operating Cash Flow
-2.0M
↑ 20.34%
Investing Cash Flow
-58.7K
↑ 135.65%
Financing Cash Flow
65.0K
↓ 4257.13%
Q4 FY22Q/Q Change
Operating Cash Flow
-1.8M
↓ 14.51%
Investing Cash Flow
-210.3K
↑ 258.43%
Financing Cash Flow
-1.6K
↓ 102.48%
Q1 FY23Q/Q Change
Operating Cash Flow
-1.3M
↓ 26.07%
Investing Cash Flow
-130.1K
↓ 38.14%
Financing Cash Flow
1.5M
↓ 94885.58%
Q2 FY23Q/Q Change
Operating Cash Flow
-2.2M
↑ 67.15%
Investing Cash Flow
-47.4K
↓ 63.57%
Financing Cash Flow
2.0M
↑ 28.15%

Technicals Summary

Sell

Neutral

Buy

Petvivo Holdings Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Petvivo Holdings Inc
Petvivo Holdings Inc
42.79%
-38.12%
-68.91%
-81.85%
-81.85%
Stryker Corporation
Stryker Corporation
-3.84%
5.16%
12.86%
24.25%
52.69%
Boston Scientific Corp.
Boston Scientific Corp.
-3.68%
21.48%
41.72%
68.89%
76.47%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-34.8%
-18.49%
-34.85%
-45.17%
-15.86%
Abbott Laboratories
Abbott Laboratories
1.03%
-5.4%
-7.12%
-11.35%
20.75%
Medtronic Plc
Medtronic Plc
-1.99%
-9.34%
-13.21%
-38.74%
-23.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Petvivo Holdings Inc
Petvivo Holdings Inc
NA
NA
0.0
0.0
-15.53
-2.39
NA
0.04
Stryker Corporation
Stryker Corporation
38.91
38.91
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.22
63.22
1.8
2.37
0.09
0.05
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
36.4
36.4
5.19
2.76
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
33.84
33.84
5.99
4.66
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
28.97
28.97
1.52
5.2
0.07
0.04
0.04
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Petvivo Holdings Inc
Petvivo Holdings Inc
Buy
$17.3M
-81.85%
NA
0.0%
Stryker Corporation
Stryker Corporation
Buy
$129.7B
52.69%
38.91
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$114.3B
76.47%
63.22
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.4B
-15.86%
36.4
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$186.6B
20.75%
33.84
13.65%
Medtronic Plc
Medtronic Plc
Buy
$102.5B
-23.49%
28.97
11.36%

Insights on Petvivo Holdings Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 595.89K → 48.26K (in $), with an average decrease of 91.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -1.74M → -2.65M (in $), with an average decrease of 51.5% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 110.6%

Institutional Holdings

  • Bard Associates Inc

    2.82%

  • Vanguard Group Inc

    1.56%

  • Geode Capital Management, LLC

    0.41%

  • State Street Corporation

    0.31%

  • Warberg Asset Management LLC

    0.19%

  • Regal Investment Advisors LLC

    0.14%

Company Information

petvivo, inc is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics. petvivo believes that it can leverage the investments in the human biomaterials and medical device industries to commercialize therapeutics to pets in a capital and time efficient way. petvivo's strategy is to in-license proprietary products from human medical device companies specifically for use in pets. petvivo, inc, gel-del technologies, inc. and cosmetalife a corporation are all wholly-owned subsidiaries of petvivo holdings, inc.

Organization
Petvivo Holdings Inc
Employees
25
CEO
Mr. John Lai
Industry
Information Technology Services

Discover More

FAQs